Compliant but Compromised: Recognizing Drug-Induced Susceptibility to Infection in Your Most Adherent Patients

When Perfect Compliance Produces Unexpected Outcomes

Clinicians are trained to suspect nonadherence when patients fail to improve. Missed doses, inconsistent schedules, and misunderstood instructions are the default explanations when a treatment course underperforms. But a distinct and underappreciated category of clinical failure exists at the opposite end of the adherence spectrum: the patient who takes every medication exactly as prescribed—and still gets sick, repeatedly, without a clear explanation.

In these cases, the regimen itself warrants scrutiny. A growing body of pharmacological evidence indicates that several widely prescribed drug classes do not merely treat disease; they simultaneously create conditions that increase susceptibility to infection. The mechanisms are diverse, often subtle, and rarely flagged during routine prescribing. Understanding them is essential to clinical practice in any setting where complex medication regimens are the norm.

The Immunosuppressant Burden: Broad Effects, Narrow Monitoring

Immunosuppressants represent the most intuitive category in this discussion. Drugs such as corticosteroids, calcineurin inhibitors, mycophenolate mofetil, and biologic agents are explicitly designed to attenuate immune function. That immunosuppression is the therapeutic goal does not, however, mean the infectious consequences are always adequately anticipated or monitored.

Long-term corticosteroid use—common in autoimmune disease, asthma, and inflammatory bowel conditions—impairs neutrophil migration, reduces lymphocyte proliferation, and disrupts the integrity of mucosal barriers. Even low-dose regimens, when sustained over months, can meaningfully blunt the innate immune response. Patients on chronic prednisone at doses as modest as 10 mg daily carry a measurably elevated risk for opportunistic infections, yet this risk is often underweighted in clinical decision-making outside of transplant medicine.

Biologic agents—particularly those targeting tumor necrosis factor-alpha—have transformed the management of rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. Their infectious risk profile, however, extends well beyond the well-publicized concern for tuberculosis reactivation. Fungal infections, atypical bacterial pneumonias, and viral reactivation syndromes all occur at elevated rates in this population. Clinicians managing these patients in primary care or outpatient specialty settings may not always maintain the heightened index of suspicion these regimens demand.

Proton Pump Inhibitors: A Case Study in Underestimated Risk

Proton pump inhibitors occupy a peculiar position in this discussion. They are among the most prescribed medications in the United States, frequently initiated for indications that range from well-established to marginally justified. Their safety profile is generally considered favorable, and their mechanism—inhibition of the gastric hydrogen-potassium ATPase pump—appears mechanistically remote from immune function.

The clinical reality is considerably more complex. Gastric acid serves as a primary nonspecific defense against ingested pathogens. By raising gastric pH to levels that allow bacterial survival, PPIs effectively disable one of the body's most efficient microbial checkpoints. The consequences are measurable: long-term PPI use is associated with increased rates of Clostridioides difficile infection, community-acquired pneumonia, and small intestinal bacterial overgrowth.

The microbiome disruption associated with chronic PPI therapy deserves particular attention. Alterations in the gut microbial community—specifically reductions in protective Lactobacillus and Bifidobacterium species—have been documented in patients on sustained PPI regimens. These changes reduce colonization resistance, the phenomenon by which a healthy microbiome prevents pathogenic organisms from establishing a foothold. The clinical result is an individual who, despite no apparent immune deficiency, is meaningfully more vulnerable to enteric infections and dysbiosis-related complications.

Antacids and the Overlooked Aluminum-Magnesium Question

Aluminum- and magnesium-containing antacids occupy the lower end of the prescribing hierarchy, frequently recommended or self-initiated for symptomatic acid relief. Their impact on infection risk is less thoroughly studied than that of PPIs but operates through comparable mechanisms. Repeated neutralization of gastric acid, even transiently, can impair the stomach's ability to sterilize ingested contents.

More relevant to clinical practice is the frequent co-prescription of antacids alongside other medications for gastrointestinal tolerability. In patients already receiving immunosuppressants or antibiotics, the additive disruption to gastric defenses and microbiome composition may compound existing vulnerabilities in ways that are difficult to attribute to any single agent.

A Framework for Recognizing Iatrogenic Immunocompromise

Identifying drug-induced infection susceptibility requires a deliberate clinical approach. The following framework offers a structured starting point for clinicians managing patients with recurrent or unexplained infections:

Step 1: Conduct a full medication audit with an infectious lens. Review every agent in the regimen—including over-the-counter medications and supplements—with explicit attention to known or plausible effects on immune function, mucosal integrity, and microbiome composition. Do not limit this review to labeled immunosuppressants.

Step 2: Characterize the infection pattern. Recurrent infections involving the same organism or anatomic site suggest a localized or specific immune deficit. Infections involving diverse pathogens or unusual organisms suggest broader immunocompromise. The pattern often points toward the mechanism.

Step 3: Assess cumulative pharmacological burden. Polypharmacy amplifies individual drug risks. A patient on a PPI, a low-dose corticosteroid, and a biologic agent carries a compounded infectious risk that exceeds what any single agent would predict. Cumulative burden should be calculated, not assumed to be additive in a simple linear sense.

Step 4: Evaluate the necessity of each contributing agent. Deprescribing is not always feasible, but it is often underutilized. PPIs initiated for stress ulcer prophylaxis during a hospitalization and continued indefinitely represent a common and modifiable risk. Corticosteroid tapers that are prolonged beyond clinical necessity represent another. Each agent on the regimen should have a current, documented indication.

Step 5: Consider prophylactic or restorative strategies where evidence supports them. Pneumocystis prophylaxis in patients on sustained high-dose corticosteroids, antifungal coverage in certain biologic recipients, and probiotic supplementation in long-term PPI users are all interventions with evidence-based rationale. These should be considered proactively rather than reactively.

Reframing the Clinical Narrative

The patient who presents with recurrent sinusitis, unexplained urinary tract infections, or a third episode of pneumonia in two years is not necessarily unlucky. In a substantial proportion of such cases, the medication regimen has quietly dismantled the defenses that would otherwise contain these infections. Recognizing this requires clinicians to hold two ideas simultaneously: that medications are therapeutic, and that they are never without biological consequence.

At EdMedRxP, the principle underlying precision prescribing is that every pharmacological decision carries downstream effects that extend beyond the primary therapeutic target. Infection risk is one of the most consequential—and most frequently overlooked—of those effects. Bringing it into sharper clinical focus is not an argument against necessary therapy. It is an argument for prescribing with full situational awareness, monitoring with appropriate vigilance, and intervening before iatrogenic vulnerability becomes irreversible harm.